The Centers for Medicare & Medicaid Services (CMS) is launching a new program on April 1, 2026, to cover up to $500 worth of hemp-derived products for eligible Medicare patients. This initiative has garnered attention from various stakeholders, including Mehmet Oz, who has been vocal about healthcare reforms. The program primarily focuses on cannabidiol (CBD) products but also permits a limited amount of tetrahydrocannabinol (THC) in these offerings.
Immediate circumstances surrounding the program reveal a legal challenge from individual plaintiff David Evans, who claims he has standing as a Medicare recipient. However, federal agencies have rejected his claims, stating that he has not been harmed by the Medicare hemp program. The government has filed a brief asserting that anti-cannabis organizations lack standing to contest the policy, emphasizing that their opposition is part of their organizational missions.
Judge Trevor N. McFadden has already dismissed the plaintiffs’ request for a temporary restraining order to prevent the program from launching. This ruling underscores the government’s position that the Medicare hemp coverage policy is legally sound and ready for implementation. The program is designed as a voluntary component of existing models, allowing healthcare providers to consult with consenting beneficiaries about eligible hemp products.
CMS clarified that it will not directly pay for hemp products under the Beneficiary Engagement Incentive (BEI). Instead, providers will furnish eligible products at their own cost, operating within a shared-savings framework that defines the underlying models. This approach aims to improve access to full-spectrum CBD products, which has been a focus of recent healthcare discussions.
In addition to the Medicare hemp program, the White House Office of Management and Budget has been involved in discussions regarding a Food and Drug Administration (FDA) enforcement policy for CBD products. The FDA has issued guidance indicating it does not intend to interfere with the Medicare hemp-derived products coverage plan, further legitimizing the program’s rollout.
Historically, the Medicare hemp coverage program was announced as part of an initiative to enhance access to CBD products following an executive order signed by former President Donald Trump. This context highlights the evolving landscape of healthcare policies concerning cannabis-derived products and their integration into mainstream medical practices.
Reactions to the program have varied. The government brief noted that Mr. Evans opposes hemp products and will not use them, which raises questions about the motivations behind the legal challenge. Additionally, the brief stated, “Their expenditure of resources to oppose it is the execution of their organizational missions, not a diversion from them,” indicating a broader debate on the role of advocacy groups in shaping healthcare policies.
As the Medicare hemp coverage program prepares for its launch, stakeholders are closely monitoring its implementation and the potential implications for healthcare access and cannabis policy. With the ongoing discussions involving figures like Mehmet Oz, the program is positioned at the intersection of healthcare reform and evolving societal attitudes towards hemp and cannabis products.
